i-GENTIC AI has enhanced its GENIE platform to streamline compliance with FDA regulations throughout the product approval lifecycle in the life sciences sector.
GENIE, a pioneering intelligence engine, translates complex regulatory requirements into machine-executable logic, facilitating real-time compliance. This innovation addresses a significant challenge faced by biopharma and medtech companies: ensuring consistency across vast amounts of documentation during the approval process. Zahra Timsah, the founder and CEO of i-GENTIC AI, emphasizes that GENIE continuously validates claims and data across submissions, thereby reducing the likelihood of regulatory delays caused by conflicting information.
The platform operates by breaking down relevant documents into machine-readable components, allowing it to cross-reference terms and concepts at a granular level. For instance, if discrepancies arise in clinical efficacy data, GENIE not only identifies these inconsistencies but also suggests corrections, tracing back to the original sources. This proactive approach minimizes review cycles and enhances the efficiency of regulatory submissions.
Furthermore, GENIE's real-time governance capabilities allow compliance teams to validate documents as they are authored, rather than relying on post-submission checks. This shift from reactive compliance to continuous enforcement represents a critical evolution in how life sciences organizations manage regulatory requirements. By embedding governance directly into workflows, i-GENTIC aims to transform compliance from a bottleneck into a streamlined process, ultimately fostering innovation while maintaining rigorous oversight.
As the life sciences industry increasingly relies on advanced AI technologies, the integration of tools like GENIE could prove essential in navigating the complexities of regulatory compliance, ensuring that innovation does not compromise safety and efficacy.